New docking molecules were predicted to fit into the RSV prefusion F stabilized central cavity including those of fusion-inhibitor resistant mutations. The new top candidates predicted low picoMolar affinities to F, low nanoMolar affinities to most fusion-inhibitor resistant mutations, low toxicity risks and high specificity to target similar trimer cavities than the crystallographic inhibitor binding. The new top candidates belong to compact 3 star-like molecules fitting the 3-fold symmetric internal RSV F cavity contacting more amino acids than the inhibitory drugs. Chances are that some of the new candidates may also interfere the conformational changes required for RSV fusion.